Sucampo Submits NDA For Constipation Agent Lubiprostone

Standard review is expected, setting a user fee deadline in January 2006. Sucampo plans to begin Phase III trials in constipation-predominant irritable bowel syndrome “soon.” The oral agent would be marketed by Takeda’s U.S. subsidiary.